Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

CNBC

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

EconomyDaily Composite
ShareXFacebook

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

C

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement